Zydus Lifesciences inches up on getting USFDA’s final nod for Famotidine Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 364.60, up by 1.65 points or 0.45% from its previous closing of Rs. 362.95 on the BSE.
The scrip opened at Rs. 360.00 and has touched a high and low of Rs. 364.60 and Rs. 358.00 respectively. So far 6682 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.85 on 11-Jun-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 381.90 and Rs. 358.00 respectively. The current market cap of the company is Rs. 37156.74 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.44% and 9.69% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Famotidine Tablets in the strengths of 20mg and 40mg. Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid in the stomach. It is used to prevent and treat heartburn and other symptoms caused by excessive acid in the stomach (acid indigestion). The drug will be manufactured at group’s drug formulation facility at SEZ, Ahmedabad.
Famotidine Tablet has a market size of $67 million (as per IQVIA MAT April 2022). The group now has 315 approvals and has so far filed over 420 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
